Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 9/20 | 0.42 |
| ▸ | CTSL | P07711 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15627225 | 0.85 | CTSK (0.46) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL17282840 | 0.84 | CYP2D6 (0.48) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL28631346 | 0.84 | CYP2D6 (0.48) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL15627223 | 0.84 | CYP2D6 (0.48) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL6381798 | 0.84 | CTSK (0.52) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL26996492 | 0.83 | CTSK (0.65) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL26996553 | 0.83 | CTSK (0.65) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL31606449 | 0.80 | CYP2D6 (0.53) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL13538162 | 0.80 | CYP2D6 (0.53) | CTSKCYP2D6CA1CA2CA7 | |
| SCHEMBL14931110 | 0.80 | CYP2D6 (0.53) | CTSKCYP2D6CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9751877-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2897956-B1 | NOVEL BICYCLIC PYRIDINONES | PFIZER (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2016-01-28 | — | — | US | disclosed |
| US-9193726-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PFIZER INC. | 2015-03-12 | — | — | US | disclosed |
| US-8916564-B2 | Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders | PFIZER INC. (US) | 2014-12-23 | — | — | US | disclosed |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | PFIZER INC. (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150072990-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use In The Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | CTSK 3178/4885CYP2D6 146/4885CA1 3654/4885 |
| US-20140088111-A1 | Novel Bicyclic Pyridinones | CYP2B6, CYP2D6, CYP2C19 | CTSK 2751/4885CYP2D6 2/4885CA1 4522/4885 |
| US-20160024088-A1 | Novel Pyrido[1,2-a]Pryazines And Their Use in the Treatment of Neurodegenerative and Neurological Disorders | PRNP, SNCA, PSEN1 | CTSK 3178/4885CYP2D6 146/4885CA1 3654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.